Turkish soil bacterium provided vital antibiotic, but Turkey missed out on commercial success
A bacterium taken from the soil in Eastern Anatolia, Turkey, many years ago has proven to be the source of one of the world' s most significant antibiotics, daptomycin.
Despite the bacterium' s Turkish origins, Turkey has not received any commercial share of the multi-billion dollar success the drug has enjoyed internationally.
This is a fact that the Turkish scientist Ali Rıza Akın has recently brought to light. The bacterium in question, identified as Streptomyces roseosporus, originates from samples that were transported from Turkey to the USA.
It was subsequently used there as the basis for the development of daptomycin.
The drug is now known under the brand name CUBICIN on the American market and is recognised as a critical tool in the fight against serious bacterial infections. Daptomycin belongs to an important class of antibiotics and is crucial in the treatment of infections caused by resistant bacteria, such as MRSA.
The development of new antibiotics is a global priority due to the growing threat of antibiotic resistance, which makes the discovery of Streptomyces roseosporus and its properties particularly valuable. This story highlights Turkey' s enormous biological diversity, especially in the Anatolian region, which is known for its unique flora and fauna.
Such natural areas are often unexplored sources of biological material that may contain undiscovered substances with potential for medical or industrial applications.
The process of searching for and extracting valuable compounds from nature, known as bioprospecting, is an increasingly important part of modern research and development. The lack of commercial return for Turkey in this case represents a significant economic loss.
Had there been a framework in place to secure a share of the revenue from products developed from Turkish genetic resources, it could have generated large sums that could have been invested in research, development, and the conservation of Turkey' s biological heritage.
It demonstrates how important national strategies for the management and commercialisation of such resources are. The case of daptomycin is a reminder of the strategic value of biological resources and the importance of establishing clear guidelines for how they can be utilised for national benefit.
For Turkey, this means an opportunity to strengthen legislation and institutional frameworks to protect its genetic resources and ensure fair benefit-sharing from future discoveries.
This includes investments in domestic research and development, as well as establishing partnerships that ensure Turkey receives a share of the value creation. Internationally, this type of incident highlights the global discussions surrounding sovereignty over genetic resources and the principles of prior informed consent and benefit-sharing.
Many countries, including Turkey, have significant potential to contribute to global medicine and technology through their biological diversity.
By learning from such past cases, Turkey can position itself better to ensure that future innovations based on the country' s unique natural heritage also benefit the Turkish economy and society.
Source: Haberglobal
